Schering Plans For Possible Clarinex Switch By Readying OTC Division
This article was originally published in The Tan Sheet
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
You may also be interested in...
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Schering-Plough will retain its Consumer Health Care business in the near-term but may choose to sell the unit as it undertakes a broad restructuring plan that includes an unprecedented dividend slash to cut costs
Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7